HC Wainwright & Co. reiterated coverage on ATAI Life Sciences with a new price target
$ATAI
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. reiterated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $50.00 from $40.00 previously